Novo nordisk a/s: once-weekly sogroya® (somapacitan) receives chmp positive opinion for expanded use in children and adolescents with growth hormone deficiency

BagsvÆrd, denmark , 26 may 2023 – novo nordisk today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion, recommending once-weekly sogroya® (somapacitan) for replacement of endogenous growth hormone (gh) in children aged three years and above, and adolescents with growth failure due to growth hormone deficiency.
NVO Ratings Summary
NVO Quant Ranking